Member Info for HereforHemo

Cat I’m pretty certain we’ll do an offtake but not sure about a JV. It wouldn’t surprise me if they went down the debt route and even financed the plant themselves. That would give them the option for additional revenue from processing any other helium that is found in Tanzania. HE1 seem to be thinking big so nothing would surprise me.

The way this is rising anyone would think they’ve got a cure for one of the most evil cancers around.

Imagine having a unique solution to a multi billion dollar market.

I wonder what that would be worth?

#savinglives #yearsandbillions #goHemo

Micky it’s not ‘only’ 10 grand. That’s a big investment. Don’t let anyone tell you otherwise.

Pub largely agree with you:

Short-term (next 2 months): 3p

Medium-term (6-12 months): 5-7p

Stamford good to know helium is still being mentioned and promoted in government circles.

There will be an RNS this week confirming the official start of the trial.

There will be an interview with Vlad.

The SP will continue it's upwards trajectory.

Watch this space.

It showed real confidence to not only move into a purpose-built lab in 2021, but to include your own manufacturing facility.

The Company's new 10,000 rentable square feet lab will include two clean rooms purpose-built by Janus, allowing it to pursue commercialisation of its major cell therapy product candidates by manufacturing cells in-house, starting with its HEMO-CAR-T cell therapy for the treatment of acute myeloid leukemia.

Dr Vladislav Sandler, Co-Founder and Chief Executive Officer, Hemogenyx Pharmaceuticals, commented: "I am very excited to be on the West Side of Manhattan in the historic Manhattanville Factory District. Having toured every life sciences option in the New York City area, the choice for our lab's continued growth was clear. With several current and future vivarium options, the opportunity to collaborate with nearby Columbia University and City College, the convenient location for our staff, and Janus's commitment to the life sciences industry and our company, the Mink Building represents an unmatched combination of advantages. We will be growing our staff and operations significantly over the next three years, and this lab and building provide us everything we need".

Always found this part of the quote exudes confidence in the science.

"Janus also provides us with the critical flexibility we need for our future, by allowing us to grow out of this lab and into its numerous other properties in the District without penalty."

Micky it's good to see you in a better frame of mind. Been a nightmare journey but for you in particular I hope the destination makes it all worthwhile. Good luck mate.

Regardless of whether 3 is few, it's obviously been a few weeks now, even you'd agree to that. The reason I stated that was not based on Lornas comment but on the President of Tanzania's comment she wanted mining licences for companies going into production fast tracked. The reality is that it'll be issued when its issued and I maintain that will only come after we have been granted ESIA approval, so that's the one we should be looking out for. But, like some others on here, I think we'll get details on the Feasibility Study first.

The the clinical trial starting next week I'm pretty sure all concerned will want to have the first patient injected in order to discuss it at the ASH conference in early December.

RNS next week imo confirming the trial has commenced, a further RNS and interview upon first patient injected.

Exciting times ahead.

https://www.hematology.org/meetings/annual-meeting

Micky the only reason it dropped was the placing shares. They've been churned through and with the CAR-T trial officially starting next week I highly doubt the SP will be falling anytime soon.

Blubay thanks, useful info, my misunderstanding.

Just to clarify, my earlier post did NOT refer to Pumpkin falling down the well.

I expect a strong bounce today after yesterday's false drop. GLA.

Roger today's RNS was another important step in derisking from explorer to producer, and thus becoming revenue generating. However there will be no spud next week, at least to my understanding as I believe after the Form 2 approvals, there is now a 30 day notice period before drilling can commence, then they'll ramp them up quite quickly.

'Prevail must be furious' Don't you love it when woke individuals are offended on behalf of others lol.

If you're buying at nearly a 300% uplift on the current SP there is another view. They are a strategic partner with total confidence it'll soon be well above that price.

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals"

I was told by a major shareholder last night the hospital space is allocated and they are ready to go. They'll be no 'Hemo' delay this time around.

"A Site Initiation Visit (SIV) is expected to take place in the third week of November, marking the official launch of the Phase I clinical trial".

I expect a strong bounce today after yesterday's false drop. GLA.

I did say they'll be approved this week, onwards and upwards. Should be an excellent end to the year.

Micky I believe they have enough cash to commence the CAR-T trial and to prove Phase 1 with enough patients that other partners will come in and take it forward, either through licencing or purchase.

The hospital are best in class and they must be comfortable with funding to allow the trial to commence, Prevail from what I see of their company portfolio only back successful companies and Hemogenyx wouldn't have built their own manufacturing lab if they weren't confident in their scientific capability.

70% of companies progress through Phase 1 trials and as and when they do I believe Hemogenyx will get all the money they require from majors to take it through additional phases.

The trial officially starts next week, everything is in place medically, logistically and scientifically and the odds are stacked in our favour.

That's my take on it and if I'm right the SP will be multiples of the current SP.

Rest assured if there were any concerns with Hemogenyx they would not be planning another trial scheduled for early next year.

Bear in mind that Hemogenyx have two members advising Vlad that are responsible for bringing two of the five most successful drugs to market, and its worth looking at the Prevail website

the individuals choosing their investment targets have on average 25 years industry experience.

A little more faith and patience is all that's required, in my opinion anyway.

Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to children suffering from the otherwise largely incurable life-threatening diseases, AML and ALL, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in pediatric relapsed/refractory AML and ALL. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company, once again at a price very substantially above the Company's existing share price, demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukaemia and a subset of acute lymphoblastic leukaemia in children. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the Company to a significant value inflection point through the completion of its planned clinical trials.

Pw you know where the filter button is.